dupilumab

01/01/2020 - "Short-term safety outcomes from clinical trials did not reveal new safety concerns with dupilumab. Overall, evidence for the efficacy of most other immunosuppressive treatments for moderate to severe atopic eczema is of low or very low certainty. "
09/01/2021 - "Dupilumab is highly effective in treating atopic dermatitis (AD). "
12/01/2022 - "Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. "
04/19/2022 - "Dupilumab has proven to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. "
01/01/2022 - "Dupilumab has proven safe and effective in children and adolescents with atopic dermatitis (AD) in clinical trials. "

08/09/2023 - "Dupilumab was highly effective for the treatment of severe asthma and ECRS/CRSwNP, even in patients switched from other biologics without a treatment interval."
10/18/2021 - "Therefore, the treatment was switched to dupilumab, and the condition of the paranasal sinuses and middle ear greatly improved with the best control of her asthma. "
01/01/2021 - "After 4 weeks of treatment with dupilumab, all patients experienced remarkable improvement in both severe asthma and nasal polyposis. "
01/01/2021 - "The forced expiratory volume in 1 second and 6-item asthma control questionnaire scores were also markedly improved with dupilumab vs placebo. "
11/01/2023 - "Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 asthma on high- or medium-dose ICS."

01/01/2020 - "Generally, dupilumab significantly improved signs and symptoms of AD, including pruritus and patient quality of life, compared with placebo in the Japanese cohort, consistent with the overall study population. "
08/01/2023 - "Biweekly treatment with dupilumab led to an immediate improvement in itching, which subsided entirely after a few doses without any significant adverse effects. "
07/01/2023 - "Dupilumab is effective and tolerable in adult PN patients with significant improvement in skin lesions, itching, and quality of life."
12/01/2022 - "Weekly average peak pruritus Numerical Rating Scale and Dermatology Life Quality Index also improved consistently and significantly with dupilumab versus placebo, regardless of age of onset. "
08/01/2021 - "Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile."

10/17/2023 - "The introduction of biologics in the management of chronic rhinosinusitis with nasal polyposis (CRSwNP) has allowed new therapeutic options and Dupilumab represents the first approved biological agent. "
11/11/2022 - "Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). "
01/01/2024 - "Long-Term Efficacy of Dupilumab for Eosinophilic Chronic Rhinosinusitis."
05/01/2021 - "Our objective was to evaluate the efficacy of dupilumab in AERD patients with uncontrolled, chronic rhinosinusitis with nasal polyposis (CRSwNP). "
01/01/2024 - "In recent years, dupilumab has been available for the treatment of refractory chronic rhinosinusitis since 2020 in Japan. "

07/01/2023 - "In recent years, some biologics have been shown to be very effective in treating refractory CRSwNP, of which dupilumab has attracted much attention as the first monoclonal drug approved to treat nasal polyps. "
01/01/2022 - "Patients who underwent FESS had a greater improvement in nasal polyp score (5.18 ± 2.01) compared with patients treated with dupilumab (4.27 ± 1.98, p = 0.02). "
11/05/2023 - "This study aimed to evaluate the effectiveness and safety of dupilumab during the first year of treatment in a real-life setting, focusing on improvement in nasal polyp score (NPS) as well as specific symptoms, quality of life and olfactory function. "
11/18/2023 - "Dupilumab rapidly improved sinonasal symptoms and reduced the nasal polyp score 24 weeks after initiation. "
12/01/2023 - "However, the association of dupilumab-associated OSR (DA-OSR) for nasal polyps (CRSwNP) treatment has not been studied. "